GlassScriptPhysician profile
Suzanne M Kimble
NPI 1396407045
$1,894.81
in general payments reported to CMS, 2019-2025
18 companies · $659 in 2025
The $659 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $539 · 2023: $377 · 2024: $320 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $457.49 | 2022-2025 | |
| Abbvie INC. | $347.14 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $193.60 | 2022-2025 | |
| Hologic Sales and Service, LLC | $145.25 | 2024-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Medtronic, INC. | $137.18 | 2024 | Abre |
| Exeltis, USA INC. | $109.03 | 2022-2025 | Slynd |
| Sumitomo Pharma America, INC. | $99.72 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $78.52 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $59.01 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $50.31 | 2022-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $48.89 | 2022-2025 | Gardasil 9 |
| Galderma Laboratories, L.P. | $42.83 | 2022-2025 | Dysport |
| Therapeuticsmd, INC. | $33.34 | 2022 | |
| Coloplast Corp | $23.85 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.67 | 2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.63 | 2025 | Zepbound |
| Shield Therapeutics INC | $16.85 | 2023 | Accrufer |
| Avion Pharmaceuticals | $15.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Kimble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.